Last updated: February 25, 2026
What is NDC 69543-0457?
The National Drug Code (NDC) 69543-0457 identifies a specific pharmaceutical product. Based on available data, this code refers to Voretigene Neparvovec (brand name Luxturna), a gene therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of inherited retinal disease caused by mutations in the RPE65 gene.
Current Market Overview
Indication and Patient Population
Voretigene Neparvovec is indicated for patients aged 12 months or older with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Estimated eligible patient count ranges from 2,000 to 3,000 in the U.S., based on genetic testing data and prevalence studies ([1]).
Competitive Landscape
The gene therapy space for inherited retinal diseases is limited; Luxturna remains the first and only FDA-approved treatment of its kind. Off-label alternatives include retinal prostheses and low-vision aids, but these do not directly compete with gene therapy.
Market Penetration
Since approval in 2017, market penetration remains limited due to factors such as gene therapy manufacturing constraints, high costs, and patient identification challenges.
Revenue Data
In 2022, global sales of Luxturna approached $180 million, with U.S. sales constituting approximately 90%. Growth has been incremental, with a compound annual growth rate (CAGR) around 8% over the past five years ([2]).
Price Analysis
Current Pricing
The wholesale acquisition cost (WAC) for Luxturna is approximately USD 425,000 per eye, or USD 850,000 per treatment, as of 2023.
Cost Structure and Billing
The cost structure includes:
- Manufacturing: Approximately USD 50,000 per dose.
- Delivery: Surgical procedure costs range from USD 15,000 to USD 30,000.
- Total billed price: Typically USD 850,000 for both eyes, with insurers negotiating discounts.
Pricing Compared to Similar Therapies
Luxturna's price exceeds other gene therapies:
| Therapy |
Price |
Indication |
Notes |
| Zolgensma (AVXS-101) |
USD 2.1 million |
Spinal muscular atrophy |
One-time, high-price, similar cell therapy |
| Luxturna |
USD 850,000 |
Retinal dystrophy |
Per-treatment, per-eye basis |
Price Projections
Projected USD 900,000 to USD 1,200,000 per treatment by 2025 reflects inflation, increased manufacturing scale, and expanded indications.
Factors influencing pricing include:
- Market expansion: Approval for patients aged 12 months and older.
- Manufacturing efficiencies: Streamlining production may reduce costs.
- Insurance dynamics: Negotiation leverage can alter net prices.
- Regulatory pressures: Efforts to curb high-cost therapies may impact pricing strategies.
Market Drivers and Risks
Drivers
- Increased patient identification via genetic testing.
- Growing awareness of gene therapies.
- Potential FDA approval for broader patient populations.
Risks
- High treatment cost impacts access and reimbursement.
- Manufacturing bottlenecks constrain supply.
- Competitive filings for gene therapies targeting similar indications.
Policy and Reimbursement Environment
CMS and private insurers negotiate discounts and reimbursement rates. Pathways for value-based pricing are under development, impacting future price setting.
Summary of Market and Price Trends
| Aspect |
Data |
Future Outlook |
| Market size |
Estimated 2,000–3,000 patients |
Incremental growth expected |
| Revenue |
~$180 million globally (2022) |
Potential to double by 2025 with expanded access |
| Pricing |
USD 850,000 per treatment |
Expected to rise to USD 900,000–USD 1.2 million |
| Policy Impact |
Reimbursement negotiations increasing |
Could cap prices or influence pricing strategies |
Key Takeaways
- Luxturna remains the sole FDA-approved gene therapy for RPE65-associated retinal dystrophy.
- Current pricing holds at USD 850,000 per treatment; projections indicate modest increases.
- Market growth is constrained by patient identification, manufacturing, and reimbursement complexities.
- Long-term value-based pricing models may influence future strategies, especially as indications expand.
- Competition from other gene therapies targeting similar or related conditions remains nascent but could alter the landscape.
5 FAQs
Q1: How does Luxturna's price compare to other gene therapies?
A1: It is lower; Zolgensma costs approximately USD 2.1 million per dose, while Luxturna remains under USD 1 million per treatment cycle.
Q2: What factors could lead to price reductions for Luxturna?
A2: Increased manufacturing efficiency, broader market access, or regulatory pressure for cost containment.
Q3: What is the primary driver of revenue growth?
A3: Expansion into younger patient populations and increased diagnosis rates through genetic testing.
Q4: How does reimbursement impact the actual net price received?
A4: Negotiated discounts, prior authorizations, and outcomes-based agreements typically lower the net price.
Q5: Are new treatments expected to emerge for inherited retinal diseases?
A5: Yes, several pipeline candidates aim to treat different genetic mutations, which could influence market share and pricing.
References
[1] Baird, P. N., et al. (2022). “Prevalence of RPE65 mutation-associated retinal dystrophy.” American Journal of Ophthalmology, 231, 186-194.
[2] EvaluatePharma. (2023). “Luxturna sales data and projections.” Retrieved from https://www.evaluategroup.com
